ClinicalTrials.gg

Program

ZSP1273

Also written as “ZSP1273 600 mg”, “ZSP1273 200 mg” and “ZSP1273 granules”.

Its studies are mostly in Influenza, Human · Renal Insufficiency, led by Guangdong Zhongsheng Pharmaceutical.

Furthest: phase 3, since Dec 13, 202014 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Guangdong Zhongsheng Pharmaceutical140 open or runningphase 3since Dec 13, 2020Sep 18, 2018none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 18, 2018First study: phase 1 study in Influenza, HumanFirst studyNCT03679143 · 103 enrolled · China
  2. Jul 10, 2019Phase 2 study in Influenza ANCT04024137 · 172 enrolled · China
  3. Dec 13, 2020Phase 3 study in Influenza ANCT04683406 · 750 enrolled · China
  4. Sep 29, 2021Phase 1 study in Drug-drug InteractionNCT05108051 · 36 enrolled · China
  5. May 4, 20232 phase 1 studiesNCT05873426, NCT05856513
  6. Jun 27, 2023Phase 1 study in Drug Drug InteractionNCT05942365 · 28 enrolled · China
  7. Jul 6, 2023Phase 1 study in Drug Drug InteractionNCT05954624 · 49 enrolled · China
  8. Nov 20, 20232 phase 1 studiesNCT06157450, NCT06164431
  9. Jan 31, 2024Phase 1 study in Renal InsufficiencyNCT06248567 · 16 enrolled · China
  10. Oct 14, 2024Phase 2 study in Influenza aNCT06656026 · 72 enrolled · China
  11. Nov 13, 20252 phase 3 studiesNCT07229820, NCT07229807

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07229820Influenza A · China3CompletedDec 22, 2025157
NCT07229807Influenza a · China3CompletedJan 17, 2026120
NCT06656026Influenza a · China2CompletedJun 30, 202572
NCT06248567Renal Insufficiency · China1CompletedApr 30, 202416
NCT06164431Bioequivalence · China1CompletedDec 15, 202332
NCT06157450Elder · China1CompletedNov 1, 202332
NCT05954624Drug Drug Interaction · China1CompletedNov 20, 202349
NCT05942365Drug Drug Interaction · China1CompletedJul 21, 202328
NCT05873426Pharmacokinetics · China1CompletedApr 28, 20236
NCT05856513Hepatic Impairment · China1CompletedJul 4, 202324
NCT05108051Drug-drug Interaction · China1CompletedMar 17, 202136
NCT04683406Influenza A · China3CompletedApr 1, 2023750
NCT04024137Influenza A · China2CompletedMay 18, 2020172
NCT03679143Influenza, Human · China1CompletedMar 19, 2019103

How it is read

Names in the registry

  • “ZSP1273”, 11 entries
  • “ZSP1273 600 mg”, 2 entries
  • “ZSP1273 200 mg”, 2 entries
  • “ZSP1273 granules”, 1 entry
  • “[14C] ZSP1273”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.